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Abstract
Objective To investigate the effects of pioglitazone and metformin
treatment during pre-diabetic period for the prevention of diabetes in a
rat model.
Methods OLETF rats aged 18-weeks, were treated with pioglitazone
(10 mg/kg/day) and metformin (300 mg/kg/day) for 10 weeks from their
pre-diabetic period. We measured weight, lipid profiles, fat distribution,
glucose tolerance, and pancreatic insulin content.
Results Prominent weight gain (mostly subcutaneous fat area) was observed
in the pioglitazone-treated OLETF (O-P) rats versus significant weight loss was
observed in the metformin-treated OLETF (O-M) rats. Pioglitazone reversed
the serum triglyceride (TG) and FFAs levels to normal (TG 0.46 ± 0.04 vs
0.88 ± 0.05 mmol/l in LETO). At the age of 28 weeks, the O-P rats showed
completely normal glucose tolerance, and the glucose disposal rate (GDR) was
markedly improved (25.6 ± 0.4 vs 20.6 ± 0.5 mg/min/kg in O-C, p < 0.05).
The O-M rats also showed an improved fasting glucose and GDR level, but
not as much as those with O-P rats. The pancreas insulin contents were much
improved in the O-P rats (22.9 ± 1.2 vs 18.8 ± 1.3 nmol/pancreas in O-M
rats, p < 0.05) with histological improvement.
Conclusion The pre-diabetic treatment with pioglitazone, despite signifi-
cant weight gain, completely prevents to develop diabetes and enhances beta
cell function with preservation of islet cell changes. Metformin treatment
was also effective, but mainly by ameliorating the insulin resistance with
marked reduction in body weight. The reversal of dyslipidaemia and the fat
redistribution might contribute to the greater improvement of pioglitazone
treatment compared to metformin in OLETF rats. Copyright  2007 John
Wiley & Sons, Ltd.
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Introduction
Type 2 diabetes mellitus is a chronic, slowly progressive disease that is caused
by both insulin deficiency and insulin resistance. The incidence of diabetes has
been increasing rapidly, and the cost of managing the chronic complications
associated with diabetes is also becoming an enormous problem. Therefore, it
would be important to identify the high-risk patients in pre-diabetic stage and
focus on the prevention of type 2 diabetes through life-style modifications or
medication [1].
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The male Otsuka Long-Evans Tokushima Fatty (OLETF)
rat is a good animal model for examining obese type 2
diabetes mellitus. These rats are characterized by their
polygenic traits, chronic, and late onset of disease [2,3].
Between 20 and 28 weeks of age, they begin to have overt
diabetes, and around the age of 40 weeks, pancreatic
beta cell function apparently decreases and becomes
hypoinsulinaemic with defects in insulin secretion [3].
Several clinical and animal studies have shown that
troglitazone, peroxisome proliferator-activated receptor
(PPAR)-γ agonist, prevents the progression of type 2
diabetes through various mechanisms [4–8]. Pioglitazone
belongs to the thiazolidinedione class of drugs and binds
to a nuclear receptor called the PPAR-γ . It enhances
the expression of multiple genes encoding the proteins
that modulate glucose and lipid metabolism [9,10].
Pioglitazone increases insulin sensitivity mainly at the
level of muscle and adipose tissue, with some effects on
the liver. However, the accurate mechanism of this drug is
still unclear [11–13]. Pioglitazone is also known to have
some effects related to the PPAR-α receptor. This cross
reactivity to the PPAR-α may explain why pioglitazone
more effectively lowers triglyceride levels in this class
[14,15]. Metformin is also widely used as an insulin
sensitizer in clinics; There are several studies which have
shown that metformin can prevent diabetes mellitus and
hypertension in animals and humans [16–18].
Therefore, the aims of our study were to investigate
and compare the metabolic effects of well-known
insulin sensitizers, pioglitazone and metformin, and their
effectiveness in preventing the development of diabetes in
genetically determined diabetic OLETF rats with chronic
treatment from the pre-diabetic periods.
Materials and methods
Animals and diet
Male OLETF rats and their control counterpart, male Long-
Evans Tokushima Otsuka (LETO) rats, aged 4 weeks, were
kindly provided from Otsuka Pharmaceuticals, Japan.
They were maintained in a temperature-controlled envi-
ronment with a 12-h light/dark cycle and supplied with
standard rat chow diet consisting of 61% carbohydrate,
26% protein and 13% fat and tap water ad libitum. They
were maintained according to the ethical guidelines of this
institution. The Committee on Animal Investigation of the
Yonsei University approved this experimental protocol.
Administration of pioglitazone and
metformin
Pioglitazone, [(±)-5-[p-[2-(5-ethyl-2-pyridyl)ethyl]ben-
zyl]-2.4-thiazolinedione hydrochloride], which is known
as a PPAR-γ agonist, was kindly provided by Dr Hiroshi
Fukui (Takeda Chemical Industry Co., Osaka, Japan).
Standard rat chow was pulverized to a fine powder and
divided into two groups, pioglitazone and metformin.
The respective drugs were added and thoroughly mixed
to a final concentration of 0.015% (wt/wt) [piolitazone
150.02 mg/pulverized chow 1 kg] and 0.677% (wt/wt)
[metformin 6.816 g/pulverized chow 1 kg], respectively.
These concentrations were chosen based on a preliminary
study that adjusted the pioglitazone and metformin doses
to 10 and 300 mg/kg/day, respectively. The chow for
control rats was prepared in a similar manner without the
addition of drugs.
Experimental protocol
At the age of 18 weeks, the OLETF rats were randomly
divided. The LETO control rats (LETO) and OLETF control
rats (O-C) received standard chow diet only from birth
to 28 weeks (n = 10 at each). The Pioglitazone treated
OLETF rats (O-P) were maintained on the pioglitazone-
containing chow diet (n = 20, 0.015%, wt/wt) and the
metfomin treated OLETF rats (O-M) received metformin-
containing chow (n = 20, 0.677%, wt/wt) from 18 to
28 weeks of age. All the rats were housed two to a
cage and were given free access to chow and water. The
body weight and food intake of the OLETF and LETO
rats were monitored periodically from the age of 18 to
28 weeks. The mean food intake was estimated to be
the amount of food consumed per cage. At the ages of
18 and 28 weeks, an oral glucose tolerance test (OGTT)
was performed in all groups, respectively. A euglycaemic
hyperinsulinaemic clamp test was performed at the age
of 28 weeks. After the euglycaemic clamp test, all rats
were sacrificed and the abdomen was quickly opened to
remove the whole pancreas (n = 10 from each group).
The abdominal subcutaneous fat pad and epididymal
visceral fat pad were dissected and weighed.
Plasma glucose and lipid
measurements
Blood was withdrawn from the tail vein and the
blood sample was placed on ice prior to centrifugation
for 10 min. The supernatant was retained and stored
at −80 ◦C until the glucose, insulin, total cholesterol
(TC), triglyceride (TG), and non-esterified free fatty
acids (FFAs) levels were measured. The plasma glucose
level was measured by a glucose-oxidase method.
The plasma insulin concentration was measured by a
radioimmunoassay using the double-antibody method
with a commercially available radioimmunoassay kit
(Linco Research). The plasma concentrations of total
cholestrol, TG, and FFAs were measured by an enzymatic
colorimetric method using commercially available kits.
Euglycaemic-hyperinsulinaemic clamp
test
After 10 weeks of treatment, the rats were anesthetized
with sodium pentobarbital (Somnotol; 50 mg/kg, ip). The
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body temperature was maintained at 37–38 ◦C with a
heating lamp. The right femoral artery was catheterized
for blood sampling. A blood sample was obtained 20 min
after surgery to determine the basal blood glucose
concentration. Insulin was infused at a constant rate of
6 mU/kg/m via the left femoral artery with an infusion
pump (Harvard Apparatus 22; Harvard, Natick, MA).
Human insulin was dissolved in 0.9% NaCl containing
1% BSA. The glucose (25%, wt/vol) infusion was begun
5 min after the insulin infusion through a second IV
catheter with its infusion rate adjusted to sustain the
plasma glucose level at −6 mmol/l using the PACBERG
algorithm. Subsequently, 25 µl blood was sampled from
the right femoral artery at 10-min intervals, and the blood
glucose concentrations were determined within 30 s using
a glucose analyser [19,20].
Pancreas Insulin content
After a 2-h euglycaemic clamp test, the rats were sacrificed
(n = 7 in each LETO and O-C group, n = 10 in each O-
P and O-M group) and the whole pancreas was rapidly
dissected free from the surrounding tissues, weighed in
air, frozen in liquid N2, and stored at −70 ◦C. The frozen
whole pancreata were homogenized at 20 500 rpm for
20 s using a tissue homogenizer (Ultra-Turrax T24, IKA-
Labartechnik, Staufen, Germany) in a 10 times volume
(10 ml buffer solution per 1 g tissue) of an acid ethanol
buffer (1.5 Ml HCL 12 mol/l in 100 ml 70% [vol/vol]
ethanol) and incubated overnight at 4 ◦C for a further
extraction. On the next day, the samples were centrifuged
at 3000 g for 15 min at 4 ◦C, and the supernatants were
diluted 1 : 100 and refrozen at −70 ◦C until needed for the
assay. The insulin level was measured with an insulin RIA
kit for rat insulin and was normalized with the pancreas
and the total body weight (g%).
Histopathological examination
Pancreatic tissues (n = 3 in each LETO and O-C group,
n = 10 in each O-P and O-M group) were fixed overnight
in 10% formaldehyde solution and embedded in paraffin
for histological examination. Paraffin sections were
stained with hematoxylin-eosin (H&E) stain and Masson’s
trichrome stain to evaluate the degree of fibrotic change.
All histological samples were examined by the same
pathologist who was blinded to the treatment.
Statistical analysis
The inter-group comparisons were performed using an
independent samples t-test and a one-way ANOVA.
Paired samples were compared with using a paired t-
test. Significance was defined as a p value <0.05. The
group data is expressed as a mean ± SEM. The statistical
analyses were performed using the SPSS 10.0 software
package (SPSS, Inc., Chicago, IL).
Results
Food consumption and body weight
changes
During the period of study, the mean daily food intake
of the LETO and OLETF rats was similar (28.3 ± 1.1
(vs) 29.5 ± 1.5 g/d, P = NS). Chronic treatment with
pioglitazone and metformin did not influence the quantity
of food intake (26.9 ± 1.3, 26.8 ± 1.6 g/d, respectively,
Table 1). The O-P gained more weight at the end of
the study than the O-C (600 ± 14 (vs) 528 ± 14 g in
O-C rats, p < 0.05). Meanwhile, the O-M failed to gain
weight compared to the control-OLETF rats (506 ± 18 g
(vs) 528 ± 14 g in O-C rats, p < 0.05, Table 1).
Body fat distribution
The prominent weight gain in the OLETF rats after
pioglitazone treatment was primarily due to the increase
in the subcutaneous fat deposit rather than the visceral
one (4.7 ± 0.1 (vs) 3.0 ± 0.3 g% in O-C rats, p < 0.05,
Table 1). The epididymal fat contents were markedly
lower in the metformin-treated OLETF rats compared to
the other group (1.8 ± 0.1 (vs) 2.5 ± 0.1 g% in O-P rats,
p < 0.05, Table 1).
Serum insulin and glucose response to
oral glucose load
At the beginning of the study, the baseline plasma glucose
concentration and glucose intolerance of the LETO and
OLETF rats were similar (Table 1, Figure 1(A)). At the
end of the study, the fasting plasma glucose levels of the
O-C rats were slightly higher than that in the LETO rats
(5.81 ± 0.11 (vs) 4.43 ± 0.21 mmol/l, p < 0.05, Table 1).
However, after an oral glucose load, the blood glucose
level was remarkably higher in the O-C rats than the LETO
rats (Figure 1(B)). In contrast to the O-C rats, the O-P
rats showed almost normal fasting and glucose-loaded
blood glucose levels compared to those of the LETO rats
(Figure 1(B)). In the case of the O-M rats, the fasting
glucose level was similar to those in the O-P rats, in
which the post glucose-loaded levels were between those
of the O-C and O-P rats, but the peak blood glucose levels
was almost 16 mmol/l at 30 min after the glucose load
(Figure 1(B)).
From an analysis of the glucose area under the curve
(AUC), the O-P rats showed a marked improvement
in the glucose utilization rather than the O-M rats
(7.15 ± 0.98 (vs) 11.02 ± 0.75 mmol/l/h, respectively,
p < 0.05, Table 1).
Changes of plasma lipid concentrations
At the pre-diabetic stage of the 18-week-old OLETF
rats, the fasting total cholesterol and triglyceride plasma
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concentrations of the OLETF and LETO rats were similar
(Table 1). However, the fasting plasma-free fatty acid
levels of the OLETF rats were markedly higher than the
LETO rats. At the end of the study, the fasting total
cholesterol, triglyceride, and free fatty acid plasma levels
in the O-C rats were remarkably elevated compared to
those of the LETO rats (Table 1). After 10 weeks of
pioglitazone administration, the lipid profiles of the O-
P rats, particularly the serum triglyceride levels and
FFAs, were dramatically improved and reversed up to
the lower levels than those of the LETO control rats (TG
0.46 ± 0.04 (vs) 0.88 ± 0.05 mmol/l in LETO, P < 0.05,
Table 1). In the O-M rats, the plasma lipid concentrations
were also reduced, but not as profound as those in O-P
rats (Table 1).
Glucose disposal rate during
euglycaemic clamp test
In the O-C rats, the glucose disposal rate was significantly
lower during the euglycaemic clamp test than in
the non-diabetic LETO rats (20.6 ± 0.5 (vs) 26.3 ±
0.4 mg/min/kg, p < 0.05, Figure 2). Both the O-P and
O-M rats recovered the glucose disposal rate up to the
level of those in the LETO rats (Figure 2).
Pancreas insulin contents
At the age of 28 weeks, the pancreatic insulin contents
were significantly lower in the O-C rats than in the
LETO rats. In the O-P rats, the amount of pancreatic
insulin content was almost doubled compared to the O-C
rats (22.9 ± 1.2 (vs) 11.4 ± 1.1 nmol/pancreas, p < 0.05,
Figure 3), and was significantly increased compared to
those in the LETO rats. In the O-M rats, the pancreatic
insulin content was also higher than the O-C rats
but was not as high as in the O-P rats (18.8 ± 1.3
(vs) 22.9 ± 1.2 nmol/pancreas in O-P rats, p < 0.05,
Figure 3).
Histopathological changes
The pancreata of the O-C rats were hypertrophic, the
islet cells were increased in number and structurally
disarranged with early fibrosis at the age of 28 weeks
(Figure 4(B)). In the O-P rats, the structural changes in
their pancreatic tissue were much less hypertrophic and
fibrotic than that of the O-C rats (Figure 4(C)). ß cell
hypertrophy and fibrosis were also improved in the O-M
rats, but compared with the O-P rats, more inflammatory
cell infiltration and fibrosis were observed (Figure 4(D)).
Discussion
This study demonstrated that a chronic treatment with
pioglitazone in pre-diabetic OLETF rats prevents the
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Figure 1. Plasma glucose concentrations before and after oral glucose (2 g/kg) load at pre-treatment (A) at the age of 18 weeks
and post-treatment (B) at 28 weeks in LETO rats (LETO) and control-OLETF rats (O-C), the pioglitazone- (O-P) and the metformin-


















Figure 2. Glucose disposal rate (GDR) calculated during a
euglycaemic hyperinsulinaemic clamp after a 10-week treatment
of pioglitazone and metformin. a p < 0.05 (vs) LETO rats (LETO);
b p < 0.05 (vs) control-OLETF rats (O-C). O-P, the pioglitazone
treated OLETF rats; O-M, the metformin treated OLETF rats
development of diabetes, normalizes hyperlipidaemia and
increases pancreatic insulin contents despite the promi-
nent body weight gain. On the other hand, a long-term
treatment with metformin during the pre-diabetic stage in
OLETF rats does not completely reverse hyperglycaemia
after glucose loading, but significantly improves glucose
utilization with marked weight reduction.
A previous study showed that the long-term adminis-
tration of troglitazone in the OLETF rats prevents diabetes
and insulin secretory defects. However, they did not report
the marked weight changes in the troglitazone treated rats
[7]. PPAR-γ agonist is known to promote preadipocyte
growth and differentiation with subcutaneous adipocytes
being more specific than visceral adipocytes, which results



















Figure 3. Pancreas insulin contents after a 10-week treatment of
pioglitazone and metformin. a p < 0.05 (vs) LETO rats (LETO);
b p < 0.05 (vs) control-OLETF rats (O-C). O-P, the pioglitazone
treated OLETF rats; O-M, the metformin treated OLETF rats
cells [21,22]. In this study, after 10 weeks of pioglitazone
administration, the OLETF rats show a marked weight
gain, but the increased fat portions were mainly found
in the subcutaneous fats rather than in the metaboli-
cally deleterious visceral fats (Table 1). Miyazaki et al.
reported that a shift in the fat distribution from the vis-
ceral or other area to subcutaneous adipose depots after a
pioglitazone treatment is associated with an improvement
in the hepatic and peripheral tissue sensitivity to insulin in
type 2 diabetic patients [21]. This can explain the normal
glucose tolerance in the pioglitazone-treated OLETF rats,
despite their significant body weight gain in this study.
In contrast, the metformin treated groups show a
marked weight reduction compared to both the LETO
and the other OLETF groups in this study. The marked
Copyright  2007 John Wiley & Sons, Ltd. Diabetes Metab Res Rev 2007; 23: 411–418.
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(A) (B)
(C) (D)
Figure 4. Morphologic features of pancreatic islet cells at 28 weeks of age. A. LETO rats (LETO): Normal islets of LETO rat
at 28 weeks. (A1. Hematoxylin-eosin stain, ×200, A2. Masson’s trichrome stain, ×200) B. control-OLETF rats (O-C): Enlarged
hyperplastic islets of OLETO rat at 28 weeks. Increased numbers of islets cells and irregular fibrous strands separating the lobules
into clusters are noted. (B1. Hematoxylin-eosin stain, ×200, B2. Masson’s trichrome stain, ×200) C. pioglitazone-OLETF rats (O-P):
Slightly hyperplastic islets separated into clusters by thin fibrous bands are noted. Compared with B, a lesser degree of fibrosis is
seen (C1. Hematoxylin-eosin stain, ×200, C2. Masson’s trichrome stain, ×200) D. metformin-OLETF rats (O-M): Slightly hyperplastic
islets separated into clusters by relatively thin fibrous bands with mild lymphocytic infiltration are noted. (D1. Hematoxylin-eosin
stain, ×200, D2. Masson’s trichrome stain, ×200)
reduced body weight arose mainly from the decreased
visceral fat content (Table 1). In other studies, metformin
administration can lower blood pressure in the OLETF
rats with an improvement in the insulin resistance
and triglyceridaemia with a prominent weight reduction
[17,23]. Overall, metformin can ameliorate the insulin
resistance in the OLETF rats possibly through the marked
reduction in the visceral fats and enhancing the glucose
utilization.
Hypertriglyceridaemia is known to reduce the
amount of peripheral glucose utilization [24,25], inhibit
glucose-stimulated insulin release [25,26] and promote
hepatic glucose production. Elevated triglyceride levels
and ectopic fat accumulation are commonly observed in
type 2 diabetes cases, and they have direct detrimental
effect on the pancreatic beta cells, termed lipotoxicity
[12,26]. Therefore, an intensive correction of the dys-
lipidaemia can improve the insulin resistance and the
beta cell function in type 2 diabetes [27–33]. OLETF
rats develop visceral obesity and hypertriglyceridaemia at
approximately 6 weeks, which is an age before glucose
intolerance had been manifested [29]. In the course of
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diabetes in the OLETF rats, hypertriglyceridaemia might
result in significant triglyceride storage in islets, which
cause insulin secretion defects possibly by reducing the
glucokinase activity [3].
In this study, the dramatic effects of pioglitazone in
lowering the FFAs, total cholesterol and triglyceride levels
in the OLETF rats were observed. Pioglitazone reverses the
serum triglyceride and FFAs levels to completely normal
levels beyond the range in the non-diabetic LETO rats.
Metformin also has a beneficial effect on the lipid profiles,
but a marked reduction as observed in the pioglitazone
treated groups, was not observed (Table 1).
We performed a hyperinsulinaemic euglycaemic clamp
test for measuring the level of glucose utilization in
the skeletal muscle [19]. The glucose disposal rate
was significantly improved after the pioglitazone and
metformin treatment, respectively, compared to the O-
C rats (Figure 2). When compared to previous studies,
thiazolidinediones alone or combined with sulfonylurea
improves both the glucose disposal rate in the skeletal
muscle and beta cell function in the pancreas [28,33].
The pancreatic islet cells of the OLETF rats have periodic
morphological changes according to their age, (1) a near
normal stage with some sporadic changes in the same
lobule, (2) large islet cells with hyperplasia of beta cells in
the prediabetic period, (3) atrophy of the hyperplastic foci
and a loss of beta cells in the later stage, (4) dense fibrosis
and clustering of the islet cells [34]. The pancreas insulin
content and histomorphological changes were measured
at the age of 28 weeks in the OLETF rats. At that stage,
hyperplastic pancreatic islet cells were observed in the
OLETF rats, which were forced to secrete more insulin to
overcome their loss of normal insulin sensitivity [34–36].
It was interesting that we observed the conservation
of pancreatic islet changes, from such change as islet
hypertrophy and early fibrosis, in the O-P rats. We
also observe the improvement of islets in the O-M rats,
but more fibrotic changes than the pioglitazone treated
group. This pathological improvement after 10 weeks
of pioglitazone treatment might contribute that the
pancreatic insulin content almost doubled compared to
the O-C and non-diabetic LETO rats (Figure 3, Figure 4).
Considering that the pancreatic insulin content reflects
the endogenous beta cell function precisely [33,34], the
chronic treatment of pioglitazone during the pre-diabetic
periods in the OLETF rats can preserve and compensate for
the beta cell function with ameliorating the morphological
deterioration of the pancreatic islets [36,37].
Our study has several limitations. First, we did not
measure pancreatic TG contents in the pancreas of
sacrificed animals, which could explain the direct effect
of pioglitazone on the extra-fat deposition in pancreas
and the beta cell function with normalizing serum lipid
profile in OLETF rats. Second, we did not measure
adipocytokines, such as leptin, adiponectin, IL-6 etc.,
which could influence the different mechanisms between
pioglitazone and metformin treatment on the body weight
changes and the fat redistribution of OLETF rats in this
study.
The pre-diabetic long-term treatment with pioglitazone
improves the postglycaemic insulin response at a normal
level and completely prevents the development of diabetes
in a type 2 diabetic OLETF rat model despite marked
weight gain. The pancreatic insulin contents were doubled
with preservation of islet cell pathology with the dramatic
normalization of the dyslipidaemia and fat redistribution,
which plays a different role in preventing diabetes in this
model compared to the metformin treatment.
On the other hand, the chronic treatment of metformin
in the prediabetic stage also improves fasting and
postglycaemic glucose response, but not upto the level of
the pioglitazone treated groups, which occurred mainly
as a result of an improvement in visceral obesity with
a marked weight reduction and by the enhancement of
glucose utilization in the peripheral tissue.
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